Strategic M&A, Partnerships and Licensing for Global Life Sciences
Back Bay is among the very few advisors that offer both integrated strategy and investment banking solutions. Every financial advisory engagement taps into the firm’s deep experience with deal execution and ability to provide data-driven, customized insights.
We negotiate on our clients’ behalf from the strength of our analytics, insights, research-intensive knowledge and deal experience. In 2023, Back Bay Life Science Advisors entered a strategic partnership with DNB Bank to provide strategic advisory and investment banking capabilities to life science and healthcare companies. Learn more about this offering for healthcare companies, here.
Back Bay’s dedicated investment banking team has more than $23 billion in transactional experience, has forged strong relationships with major stakeholders and offers a global reach. This ensures that Back Bay’s clients are presented with the thoughtful and strategic options that result in successful transactions.
Back Bay’s investment banking clients benefit from:
Senior banking presence with extensive life science relationships and experience
Adept financial approach that combines scientific, clinical and commercial insights
Ability to convert research-based insight into credible positioning and valuation considerations
Expertise in negotiating complex deals and creative structures
Negotiating complex M&A, partnership or licensing deals for:
Biotech, pharma and medical technology companies seeking to merge, acquire or sell
Companies looking to engage in strategic asset transactions (licensing and partnering) on a regional or global basis
Small and mid-size companies looking to extend and leverage their corporate/business development capabilities
Venture-backed companies requiring an assessment of strategic alternatives — our analysis and advice becomes the basis for our execution of strategic M&A, partnerships or licensing deals
PE and VC investors seeking guidance on portfolio strategy, investments, new financing rounds and transactions
Academic institutions seeking options for their early-stage programs, including out-licensing, partnerships and company formation
Experienced, Insightful Life Science Fairness Opinion and Valuation
Back Bay Life Science Advisors provides experienced best-in-class M&A advisory and investment banking services, including sophisticated pipeline and platform valuations, as well as specialized services such as Fairness Opinions and Valuations. For our clients involved in global biopharma and medtech mergers, acquisitions, divestitures and other sophisticated corporate transactions, we help our client boards, management teams and investors confidently make informed decisions throughout the complexities of life sciences business and corporate development.
Our senior bankers have provided fairness opinions and valuation since inception of the process in the Delaware courts more than three decades ago. We understand the intricacies of scientific development and life science complexities and integrate this within the real-life deal and legal frameworks and timing, for an unparalleled, nuanced understanding of life science transactions.
Back Bay’s fairness opinion offering is a fully integrated part of our life sciences investment banking practice and execution capabilities. We bring together life sciences strategy consulting and investment banking to meet the global need for exacting, independent insight, strategy and deal execution for life sciences companies.
Connect with our investment banking team to learn more and to request a link to our podcast on best practices for life sciences fairness opinions and valuation.
LIFE SCIENCE INVESTMENT BANKING RESOURCES
The DNB//BACK BAY PARTNERSHIP > joins DNB’s global capital markets and investment banking capabilities with Back Bay’s international expertise in integrated scientific and corporate strategic consulting and execution capabilities.
Our latest release:
Navigating 2024: Innovations and Insights in Healthcare, H1 Review
Our weekly bulletin shares healthcare IPOs, follow-on offerings, M&A, and venture financing activity across the US and EU.
TIPS FOR HEALTHCARE IPOS > Back Bay Life Science Advisors and Nasdaq’s best pratices for biopharma, medtech and healthtech IPOs.
BACK BAY TRANSACTION HIGHLIGHTS > Back Bay has completed nearly 1,000 assignments across stage and sector. View our work and learn more about our transaction capabilities.
Look to Back Bay experts for:
Mergers, acquisitions & divestitures
Private & public company, cross-border capabilities
Partnering & strategic alliances
Financing support
Fairness opinion, valuation
Registered broker-dealer
Integrated Strategy and Investment Banking
STRATEGY AND INVESTMENT BANKING SUPPORT TO A BIOTECH COMPANY DEVELOPING NOVEL THERAPIES FOR A BROAD RANGE OF PAIN INDICATIONS
Centrexion Therapeutics, a late clinical-stage biopharmaceutical company developing and commercializing novel, non-opioid and non-addictive therapies for the treatment of chronic pain, sought Back Bay strategic and investment banking experts for pipeline strategy, crossover $67MM venture round financing and out-licensing of CNTX-0290, a Phase I SSTR4 asset for potential consideration of up to ~$1 billion.APPROACH
- Back Bay strategy and investment banking worked with Centrexion management on overall corporate and R&D strategy relating to the company’s pipeline
- We supported ongoing initiatives, served as primary external diligence support leading to a successful $67 million fundraise
- Upon identification of significant deal interest in CNTX-0290, Back Bay engaged in deal strategy and negotiations with the goal supporting go/no go decision as well as optimizing deal terms
- We conducted clinical, commercial, and transaction analytics to advise management and Centrexion board on transactional issues as well as fit with overall corporate strategy
- In addition to deal advisory and negotiations, Back Bay served as a thought partner and strategic resource for Centrexion
RESULT
Back Bay served as exclusive strategic and financial advisor on the successful licensing of Centrexion’s non-opioid pain asset, CNTX-0290, to Eli Lilly for $47.5M upfront and up to $950M in clinical and commercial milestones.